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Abstract The CXC chemokine, IL-8, is a potent chemoattrac- 
tant of neutrophils and binds to two distinct receptors, termed 
IL-8R1 and IL-8R2. These receptors hare high affinity for IL-8, 
however, only IL-8RI is specific for IL-8 whereas IL-8R2 binds 
other related chemokines, including GROa with high affinity. 
Stable Jurkat transfectants were generated expressing either 
functional IL-8R1 or IL-8R2 (J-IL8R1 and J-IL8R2). Both J- 
IL8RI and J-IL8R2 exhibited high affinity IL-8 binding (Kd 3-5 
riM) with respective receptor densities of 23,000 _+ 3,000 and 
18,500 _+ 1,500. Pre-treatment of both transfectants with 1.0 btgl 
ml B. pertussis toxin (PTx) resulted in inhibition of IL-8 mediated 
intracellular Ca 2+ mobilisation and chemotaxis, without altering 
the receptor's affinity for its ligand. This indicates that both 
receptors couple to a PTx-sensitive G-protein. Further studies 
showed that IL-8RI and IL-8R2 could mediate time-dependent 
phosphorylation of p42/I~4 MAP-kinase. In both transfectants, 
phosphorylation was maximal at 1-2 min after IL-8 stimulation 
and could be inhibited by PTx. Stimulation of J-IL8R1 and 
J-IL8R2 with GRO~ revealed that this chemokine was a more 
potent activator of MAP-kinase in J-IL8R2, an observation re- 
flected in the high affinity binding of GRO~ to IL-8R2. These 
studies indicate that chemokines are capable of activating protein 
kinases and with regards to PTx-sensitivity and MAP-kinase 
stimulation, no significant differences between IL- 8R1 and IL- 
8R2 post-receptor signalling occur during cell activation by IL-8. 
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I. Introduction 
A characteristic feature of the inflammatory response is the 
recruitment of leukocytes by chemotactic cytokines (chemo- 
kines) to areas of tissue injury. Chemokines are low molecular 
weight (8-10 kDa) proteins and consist of two distinct families, 
which differ from one another with respect o their target cell 
specificity [1,2]. These families are classified according to the 
position of the first two cysteine residues, which are either 
separated by a single amino acid (CXC-chemokines) or adja- 
cent to each other (CC-chemokines). Interleukin-8 (IL-8), the 
most widely studied CXC chemokine, is a potent chemoattrac- 
tant of neutrophils and induces a variety of cellular esponses, 
including chemotaxis, mobilisation of intracellular Ca >, exocy- 
tosis and activation ofNADPH oxidase [24]. Characterisation 
of IL-8 binding has revealed that neutrophils express two IL-8 
receptors; IL-8RI and IL-8R2 [5,6]. Both receptors hare high 
affinity for IL-8 (Kd 0.2-2.5 nM), however only IL-8R2 is capa- 
ble of binding other CXC chemokines with similar high affinity 
[7-9]. IL-8 receptors consist of seven putative trans-membrane 
domains (7-TMD) and belong to a family of G-protein coupled 
receptors [2,10]. 
A general model for chemokine mediated signal transduction 
events in phagocytes proposes that an appropriate ligand-re- 
ceptor interaction causes activation of a B. pertussis toxin 
(PTx)-sensitive G-protein and induction of phospholipase C 
activity [3]. This leads to an accumulation of diacylglycerol and 
cytosolic inositol trisphosphate [11], which in turn initiates mo- 
bilisation of intracellular Ca 2+ and protein kinase C activation 
[12,13]. It has recently been shown that 7-TMD receptors, uch 
as the f-MLP receptor [14,15], the M2-muscarinic receptor [16] 
and the ~2-adrenergic receptor [17] can mediate activation of 
the mitogen-activated protein (MAP)-kinase signalling cascade 
[18]. However, chemokine activation of this protein kinase 
pathway has not been demonstrated. MAP-kinases are known 
to be responsible for the regulation of proto-oncogenic tran- 
scription factors (c-Jun, c-Myc, c-Fos), cytoskeletal e ements, 
phospholipase A2 and other protein kinases [19]. 
IL-8R1 and IL-8R2 share a high degree of sequence homol- 
ogy, particularly within the 7-TMD, however a significant de- 
gree of amino acid variation occurs at both their extracellular 
amino-terminus and intracellular carboxyl-terminus. This sug- 
gests that both receptors not only possess different ligand- 
binding properties but may also initiate different post-receptor 
signal transduction events. Leotscher et al. [20] previously dem- 
onstrated the chemokine-induced migration of Jurkat cells 
transfected with cDNA encoding for either IL-8RI or IL-8R2. 
In the present communication we have compared IL-8 medi- 
ated post-receptor signalling events in this human T-cell line 
expressing IL-8 receptors. Both functional receptors mediated 
PTx-sensitive cellular esponses and chemokine stimulation re- 
sulted in the activation of p42/p44-MAP kinase. Our results 
indicate no significant difference between the immediate post 
receptor signalling of IL-8R1 and IL-8R2, at least with respect 
to their susceptibility o PTx and activation of MAP-kinase. 
*Corresponding author. 2. Materials and methods 
Abbreviations." 7-TMD, seven putative trans-membrane domains; IL- 
8R1/2, human interleukin-8 receptors type 1/2; J-IL8RI/2, Jurkat trans- 
fectants expressing IL-8R1/2; GRO~, IL-8 related chemokine; PTx, 
B. pertussis toxin; MAP-kinase, mitogen-activated protein kinase. 
2.1. Materials 
All reagents were purchased from Merck, Fluka and Sigma chemical 
companies. RPMI 1640 media nd additional cell culture supplements, 
including G418 (Geneticin) were obtained from Gibco-BRL. The 
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expression vectors used for the transfection ofIL-8 receptors were from 
the Invitrogen Corporation, B. pertuss& toxin from List Biochemicals 
and 125I-radiolabelled NaI was obtained from Amersham. For Western 
blot analysis, Immobilon-P (PVDF) transfer membrane was from Mil- 
lipore and the p421p44 MAP-kinase (ERK-2) polyclonal antibody (c14) 
was purchased from Santa Cruz Biotechnology. Polyclonal antibodies 
specific for p47-phox (JW-1) and p67-phox (JW-2), cytosolic compo- 
nents of the NADPH oxidase, were kindly provided by Professor 
O.T.G. Jones, Department of Biochemistry, University of Bristol. 
2.2. Jurkat cell culture 
Jurkat cells were maintained at 37°C, 5% CO2 in culture medium 
consisting of RPMI-1640, 10% (v/v) feotal calf serum, 2 mM L-glutam- 
ine, 100 U/ml penicillin and 100 pg/ml streptomycin. Stable Jurkat 
transfectants were cultured in the same growth medium supplemented 
with 0.8 mg/ml G418. 
2.3. Preparation of Jurkat transfectants express&g either IL-8R1 or 
IL-8R2 
Jurkat transfectants expressing IL-8R1 were generated using the 
pcDNA-3 expression vector, which contains an inherant neomycin 
(G418) resistance gene. A 1,112 bp cDNA fragment encoding for IL- 
8R1 was generated as outlined by Leotscher et al. [20] and sub-cloned 
into pcDNA-Y Briefly, 20/tg oflinearised pcDNA-3/IL-8R 1 was trans- 
fected into Jurkat cells (5-8 x 106 cells/800/.tl PBS) by electroporation. 
Two weeks later G418-resistant (0.8 mg/ml) Jurkat clones were selected 
by limited dilution and characterized for expression of IL-8R 1 by ~25I- 
IL-8 binding. Of four independent clones, the clone with the highest 
binding capacity was selected and termed J-IL8R1. Jurkat cells trans- 
fected with cDNA encoding for human IL-8R2 were generated as 
previously described by Leotscher et al. [20] and is refered to here as 
J-IL8R2. 
2.4. B. pertussis toxin (PTx) treatment of Jurkat cells 
Jurkat cells were washed and resuspended ata concentration of l 0  7 
cells/ml in 130 mM NaC1, 4.6 mM KCI, 5.0 mM NaHCO3, 0.05 mM 
CaC12.2H20, 20 mM HEPES (pH 7.4) and 1 g/1 D-glucose. The cells were 
incubated for 90 min at 37°C in the presence or absence of 1/lg/ml PTx, 
pelletted and then resuspended in an appropriate buffer for binding and 
functional assays. 
2.5.1251-IL-8 binding and functional assays 
Chemically synthesised IL-8 [21] was iodinated as previously outlined 
[7]. Saturation titration binding studies were performed on 1.25- 
1.5 × 106 PTx-treated/non-treated J-IL8R1 and J-IL8R2 cells. Trans- 
fectants were incubated in a range of ~25I-IL-8 concentrations (0.2 20 
nM) and specific receptor binding compared to cells incubated with the 
same range of 125I-IL-8 concentrations in the presence of 500 nM non- 
radiolabelled IL-8. The binding constant (Kd) and receptor numbers 
were subsequently determined using the method escribed by Schuma- 
cher and von Tscharner [22]. 
Calcium mobilisation and in vitro chemotaxis assays were performed 
as previously described by Loetscher et al. [20]. 
2.6. Western blot analysis of p421p44 MAP kinase (ERK-2) 
Cells were washed twice with sterile PBS and finally resuspended at
a concentration f 10 7 cells/ml. Aliquots (200 pl) of the cell suspension 
were incubated for 10-15 min at 37°C before stimulation with IL-8 or 
GRO~ and the reactions were stopped by the addition of TCA (at a 
final concentration of 10%). Precipitated proteins were recovered by 
centrifugation, washed twice in cold acetone and air dried. Protein 
pellets were resuspended in SDS-PAGE sample buffer, boiled, sepa- 
rated by electrophoresis in a 10% acrylamide gel and transferred to an 
Immobilon-P (PVDF) membrane by electroblotting. Transfer mem- 
branes were blocked and probed with an anti-p421p44 MAP-kinase 
antibody followed by an alkaline phosphatase conjugated secondary 
antibody. 
3. Results and discussion 
3.1. Characterisation of  Jurkat transfectants 
Saturat ion binding studies, using 125I radiolabelled IL-8 re- 
vealed that the J- IL8R1 and J- IL8R2 stable transfectants ex- 
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Fig. 1. PTx Inhibition of IL-8 mediated chemotaxis of J-IL8R1 and 
J-IL8R2. The IL-8 induced migration of PTx-treated (e) and non- 
treated (0) Jurkat transfectants was assessed in 48-well micro-chemo- 
taxis chambers. Each assay point was measured in triplicate and the 
values represent the mean number (+ S.D.) of migrating cells per five 
high-power fields of view. The average number of cells incubated in the 
absence of IL-8 was 25 + 4. 
pressed 23,000 + 3,000 and 18,500 + 1,500 receptors/cell re- 
spectively. Both cell lines were found to bind IL-8 with similar 
high affinity (Table 1), comparable with IL-8 binding to human 
neutrophils [7,9]. Although, Loetscher et al. [20] previously 
demonstrated the migratory characteristics of Jurkat cells 
transfected with IL-8 receptors, other chemokine-induced neu- 
trophil  functions were not addressed. Here we were unable to 
detect IL-8 stimulation of superoxide product ion in our trans- 
fectants and Western blot analysis of Jurkat cell lysates con- 
firmed the absence of p47-phox and p67-phox, cytosolic factors 
of the superoxide-generating NADPH oxidase, (data not 
shown). Similarly, by contrast o neutrophils chemokine stimu- 
lation of J-IL8R1 and J- IL8R2 did not result in release of the 
proteases N-acetyl-glucosaminidase or esterase (data not 
shown). 
3.2. Assessing the sensitivity of  Jurkat transfectants to PTx  
Signalling by chemoattractant and chemokine receptors is 
inhibited by ADP-r ibosylat ion with PTx [3,10] indicating that 
the receptors are coupled to G~ subclass of G-proteins [23]. 
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Fig. 2. PTx inhibition of IL-8 induced intracellular Ca 2+ mobilisation. 
PTx-treated and non-treated Jurkat transfectants (5 × 106 cells/ml) were 
loaded with fura-2 and stimulated with 100 nM IL-8. Fluorescence 
changes are represented as a percentage of the total fura-2 saturation 
and were standardised as previously described [39]. 
Granulocytes predominantly express the G~2i protein [24~26] 
and the closely related G~3~ [27]. The G~2~ protein has previ- 
ously been shown to directly couple to the C5a and f-MLP 
receptors [24,28]. Co-transfection of COS-7 cells with IL-8 re- 
ceptors and an accompanying PTx-resistant G~-protein re- 
vealed however that IL-8R1 and IL-8R2 may also couple to the 
Gq subclass of G-proteins, G~4 and G~l 6 [29]. Although 
T-lymphocytes and cells of myelomonocytic lineage express 
G~I 6 [30], the emigration of lymphocytes from the thymus has 
been shown to be PTx-sensitive, indicating a requirement for 
the G i subclass of G-proteins [31]. 
Pretreatment of J-IL8R1 and J-IL8R2 with 1.0/~g/ml PTx 
resulted in the inhibition of IL-8 stimulated cell migration (Fig. 
1) and similarly, inhibited the mobilisation of intracellular Ca 2+ 
(Fig. 2). The IL-8 receptors expressed in these transfectants 
therefore directly couple to the G~ subclass of G-proteins, 
closely resembling their coupling in neutrophils. Saturation 
binding studies were subsequently performed in the presence 
and absence of PTx in order to test whether ADP-ribosylation 
of the G-protein interfered with receptor-ligand interactions. 
Table 1 shows that binding of ~25I-IL-8 to both receptors is 
unaltered by PTx treatment, suggesting that although PTx ri- 
bosylation leads to uncoupling of the G~-subunit [32,33], the 
interaction of IL-8 with its receptor binding site remains unaf- 
fected. 
3.3. Chemokine induced activation of p42/p44 MAP-kinase 
(ERK-2) 
MAP-kinases, also known as extracellular-signal-regulated 
Table 1 
Characterisation of IL-8 binding to Jurkat transfectants in the presence 
and absence of PTx 
Transfectant Receptors/cell Binding constant (nM) 
- PTX + PTX 
J-IL8R1 23,000 + 3,000 2.5 3.4 
J-ILSR2 18,500 + 1,500 2.1 2.0 
kinases (ERK), are activated by phosphorylation of tyrosine/ 
threonine residues [34,35] and are responsible for the regulation 
of several different proteins, including oncogenic transcription 
factors and other protein kinases. In particular, MAP-kinase 
activation of phospholipase A2 [36] and cytoskeletal e ements 
[37] suggests a role for this protein kinase signalling cascade in 
chemokine-induced cellular responses. Stimulation of human 
neutrophils with f-MLP activates the Ras/Raf pathway [38], 
leading to phosphorylation of MAP-kinase [14,15]. 
Phosphorylated MAP-kinase is easily detected by its character- 
istic retarded electrophoretic mobility andcan be distinguished 
from the unphosphorylated form by immuno-blotting. Using 
the J-IL8R1 and J-IL8R2 transfectants, we investigated 
whether IL-8 could induce phosphorylation f p42/p44 MAP- 
kinase (ERK-2). Western blot analysis ofJ-IL8R1 and J-IL8R2 
showed that both chemokine receptors can activate p42/p44 
MAP-kinase in a PTx-sensitive manner (Fig. 3), indicating the 
involvement of a G~-protein. Both Jurkat transfectants medi- 
ated an apparent ransient activation of MAP-kinase, with 
maximum IL-8-dependent phosphorylation ccurring 1-2 min 
after stimulation (Fig. 3). A similar time-dependent activation 
of this protein kinase has been shown in f-MLP [14] and IL-8 
stimulated human neutrophils (Wirthmueller andThelen, un- 
published observation). Stimulation of the transfectants with 
GRO~ resulted in a more potent activation of MAP-kinase in 
J-IL8R2 (data not shown). A finding which correlates with the 
binding characteristics of the IL-8 receptors, ince IL-8R2 pos- 
sesses a higher binding affinity, than IL-8R1, for GRO~. 
In conclusion, stable transfection of IL-8 receptors into Jur- 
kat cells resulted in their coupling to PTx-sensitive G-proteins 
resembling the immediate signalling system found in neutro- 
phils. Our data however, suggest no significant difference be- 
tween the immediate post-receptor signalling of IL-8R1 and 
IL-8R2. On the other hand, the stable transfection of chemo- 
J-IL8R1 
PTx 
J-IL8R2 
JURKAT 
Time (sec) 0 30 60 120 300 
Fig. 3. The time-dependent phosphorylation f p42/p44 MAP-kinase 
by IL-8. Jurkat cells (2 × l0  6 cells/assay condition) were stimulated at 
37°C with 100 nM IL-8. At the indicated time intervals total cellular 
proteins were precipitated by the addition of 10% TCA and separated 
by SDS-PAGE. The proteins were electroblotted and probed with a 
polyclonal anti-p42/p44 MAP-kinase antibody (c14). 
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kine receptors into cells of haemopoeitic lineage, in this case 
Jurkat cells, provides a useful system to evaluate receptor sig- 
nalling events, particularly since the degree of receptor expres- 
sion, in this heterologous ystem, remains at a physiological 
level. Thus the modes of signalling can be examined in an 
environment comparable with that found in the short lived 
neutrophils. 
Acknowledgements: The authors wish to thank Drs M. Baggiolini, 
B. Dewald, P. Loetscher, M. Uguccioni and U. Wirthmueller for their 
support and Professor O.T.G. Jones for providing antibodies to com- 
ponents of the NADPH oxidase. This work was supported by the Swiss 
National Science Foundation (31-39744.93 B.M., 31-34121.92 M.T.). 
M.T. is a recipient of a career development award from the Swiss 
National Foundation (3130-31933.91 ). 
References 
[1] Miller, M.D. and Krangel, M.S. (1992) Crit. Rev. Immunol. 52, 
1746. 
[2] Baggiolini, M., Dewald, B. and Moser, B. (1994) Adv. lmmunol. 
55, 97-179. 
[3] Thelen, M., Peveri, R, Kernen, R, von Tscharner, V., Walz, A. 
and Baggiolini, M. (1988) FASEB J. 2, 2702 2706. 
[4] Thelen, M., Dewald, B. and Baggiolini, M. (1993) Physiol. Rev. 
73, 797 821. 
[5] Holmes, W.E., Lee, J., Kuang, W., Rice, G.C. and Wood, W.I. 
(1991) Science 253, 1278-1280. 
[6] Murphy, RM. and Tiffany, H.L. (1991) Science 253, 1280- 
1283. 
[7] Moser, B., Schumacher, C., von Tscharner, V., Clark-Lewis, I. and 
Baggiolini, M. (1991) J. Biol. Chem. 266, 10666 10671. 
[8] Lee, J., Horuk, R., Rice, G.C., Bennett, G.L., Camerato, T. and 
Wood, W.I. (1992) J. Biol. Chem. 267, 16283 16287. 
[9] Schumacher, C., Clark-Lewis, i., Baggiolini, M. and Moser, B. 
(1992) Proc. Natl. Acad. Sci. USA 89, 10542 10546. 
[10] Murphy, EM. (1994) Annu. Rev. Immunol. 12, 593-633. 
[11] Smith, R.J., Sam, L.M., Leach, K.L. and Justen, J.M. (1992) 
J. Leukocyte Biol. 52, 17 26. 
[12] Pozzan, T., Lew, D.R, Wollheim, C.B. and Tsien, R.Y. (1983) 
Science 221, 1413 1415. 
[13] Dewald, B., Thelen, M. and Baggiolini, M. (1988) J. Biol. Chem. 
263, 16179-16184. 
[14] Thompson, H.L., Shiroo, M. and Saklatvala, J. (1993) Biochem. 
J. 290, 483~,88. 
[15] Grinstein, S. and Furuya, W. (1992) J. Biol. Chem. 267, 18122 
18125. 
[16] Winitz, S., Russell, M., Qian, N.-X., Gardner, A., Dwyer, L. and 
Johnson, G.L. (1993) J. Biol. Chem. 268, 19196-19199. 
[17] Alblas, J., Van Corven, E.J., Hordijk, P.L., Milligan, G. and 
Moolenaar, W.H. (1993) J. Biol. Chem. 268, 22235-22238. 
[18] Blumer, K.J. and Johnson, G.L. (1994) Trends Biochem. Sci. 19, 
236-240. 
[19] Avruch, J., Zhang, X. and Kyriakis, J.M. (1994) Trends Biochem. 
Sci. 19, 279-283. 
[20] Loetscher, E, Seitz, M., Clark-Lewis, l., Baggiolini, M. and 
Moser, B. (1994) FEBS Lett. 341, 187 192. 
[21] Clark-Lewis, I., Moser, B., Walz, A., Baggiolini, M., Scott, G.J. 
and Aebersold, R. (1991) Biochemistry 30, 3128 3135. 
[22] Schumacher, C. and von Tscharner, V. (1994) Anal. Biochem. 222, 
262 269. 
[23] Simon, M.I., Strathmann, M.R and Gautam, N. (1991) Science 
252, 802 808. 
[24] Bokoch, G.M. and Gilman, A.G. (1984) Cell 39, 301 308. 
[25] Goldsmith, P., Gierschik, E, Milligan, G., Unson, C.G., Vinitsky, 
R., Malech, H.L. and Spiegel, A.M. (1987) J. Biol. Chem. 262, 
14683-14688. 
[26] Gierschik, E, Sidiropoulos, D. and Jakobs, K.H. (1989) J. Biol. 
Chem. 264, 21470-21473. 
[27] Itoh, H., Toyama, R., Kozasa, T., Tsukamoto, T., Matsuoka, M. 
and Kaziro, Y. (1988) J. Biol. Chem. 253, 6656 6664. 
[28] Rollins, T.E., Siciliano, S., Kobayashi, S., Cianciarulo, D.N., 
Bonilla-Argudo, V., Collier, K. and Springer, M.S. (1991) Proc. 
Natl. Acad. Sci. USA 88, 971 975. 
[29] Wu, D., LaRosa, G.J. and Simon, M.I. (1993) Science 261, 101- 
103. 
[30] Amatruda, T.T., Steele, D.A., Slepak, V.Z. and Simon, M.l. (1991) 
Proc. Natl. Acad. Sci. USA 88, 5587--5591. 
[31] Chaffin, K.E. and Perlmutter, R.M. (1991) Eur. J. Immunol. 21, 
2565-2573. 
[32] Okajima, F., Katada, T. and Ui, M. (1985) J. Biol. Chem. 260, 
6761 6768. 
[33] Sullivan, K.A., Miller, R.T., Masters, S.B., Beiderman, B., Heide- 
man, W. and Bourne, H.R. (1987) Nature 330, 758-760. 
[34] Rossomando, A.J., Sanghera, J.S., Marsden, L.A., Weber, M.J., 
Pelech, S.L. and Sturgill, T.W. (1991) J. Biol. Chem. 266, 20270- 
20275. 
[35] Nel, A.E., Hanekom, C., Rheeder, A., Williams, K., Pollack, S., 
Katz, R. and Landreth, G.E. (1990) J. lmmunol. 144, 2683- 
2689. 
[36] Nemenoff, R.A., Winitz, S., Qian, N.-X., Van Putten, V., Johnson, 
G.L. and Heasley, L.E. (1993) J. Biol. Chem. 268, 1960 
1964. 
[37] Gotoh, Y., Nishida, E., Matsuda, S., Shiina, N., Kosako, H., 
Shiokawa, K., Akiyama, T., Ohta, K. and Sakai, H. (1991) Nature 
349, 251 254. 
[38] Worthen, G.S., Avdi, N., Buhl, A.M., Suzuki, N. and Johnson, 
G.L. (1994) J. Clin. lnvest. 94, 815 823. 
[39] von Tscharner, V., Prod'horn, B., Baggiolini, M. and Reuter, H. 
(1986) Nature 324, 369 372. 
